Welcome to our dedicated page for BiondVax Pharmaceuticals Ltd. news (Ticker: bvxv), a resource for investors and traders seeking the latest updates and insights on BiondVax Pharmaceuticals Ltd. stock.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company pioneering innovative solutions in the realm of inflammation and immunology (I&I). With a robust pipeline of nanosized VHH antibodies known as NanoAbs, BiondVax is targeting diseases with significant unmet medical needs. The company has made notable strides, particularly with its leading product, an intradermal NanoAb targeting IL-17 for treating mild to moderate plaque psoriasis. This product has shown promising results in preclinical ex-vivo trials and is gearing up for human clinical trials in 2025.
BiondVax operates two main business units. The first focuses on the in-house development of biological therapeutic products, leveraging its NanoAb technology licensed from the Max Planck Society and the University Medical Center Göttingen, Germany. The second unit, Scinai Bioservices, is a boutique Contract Development and Manufacturing Organization (CDMO) that offers end-to-end services ranging from drug development to GMP manufacturing. Launched in Q3 2023, Scinai Bioservices has already secured contracts with several biotechnology companies and aims to support small biotech firms in bringing their products to market efficiently.
The company recently welcomed Liat Halpert as Head of Business Development and Sales. Halpert, with her extensive experience from Novartis, is expected to expand Scinai’s CDMO business, particularly targeting European and U.S.-based biotech companies. This strategic move is anticipated to significantly boost BiondVax's revenue and establish it as a key partner for small biotechnology firms.
In recent news, BiondVax announced successful preclinical results of its IL-17 targeting NanoAb for psoriasis treatment. Additionally, its NanoAbs for COVID-19 have shown efficacy in preclinical trials, demonstrating potential in preventing and treating viral respiratory diseases through inhalation, a convenient administration route.
BiondVax's financial stability and strategic partnerships position it well for future growth. The company continues to seek collaborative opportunities with mid and large-cap pharmaceutical companies to advance its NanoAb therapies through clinical trials and towards commercialization.
For the latest updates and detailed information, visit BiondVax’s official website at www.biondvax.com.
BiondVax Pharmaceuticals Ltd. (BVXV) announced its Q1 2021 financial results, highlighting a significant decrease in total operating expenses to NIS 6.7 million ($2.0 million) compared to NIS 20.0 million in Q1 2020. Research and development expenses also fell sharply to NIS 2.75 million ($0.83 million) from NIS 19.0 million. As of March 31, 2021, cash and cash equivalents rose to NIS 48.6 million ($14.6 million) due to a successful follow-on offering in February 2021. The company appointed Amir Reichman as its new CEO, focusing on the development of products for infectious diseases.
BiondVax Pharmaceuticals Ltd. (BVXV) reported its fourth quarter and full year financial results for 2020, showcasing a significant reduction in operating and R&D expenses. Total operating expenses for Q4 2020 were NIS 12.3 million ($3.2 million), down from NIS 45.7 million in Q4 2019. The company completed a follow-on offering in February 2021, raising $13.8 million to strengthen its balance sheet. A new CEO, Amir Reichman, aims to diversify the product pipeline and enhance the company's mission to combat infectious diseases.
BiondVax Pharmaceuticals has appointed Amir Reichman as its new CEO, effective March 2. With extensive experience in global vaccines at GSK and Novartis, Reichman aims to shift the company’s focus from a single-product model centered on the M-001 influenza vaccine to a broader portfolio of products for infectious diseases.
The strategy includes diversifying product delivery methods and developing pipelines for prevention and treatment. BiondVax is currently seeking partnerships and in-licensing opportunities while planning a shareholder meeting on April 6 to approve CEO terms and capital expansion.
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) announced the full exercise of an over-allotment option by the underwriter, acquiring 365,217 American Depositary Shares (ADS), adding to an earlier offering of 2,434,783 ADSs priced at $4.95 each. This exercise increases the total gross proceeds to approximately $13.8 million. Previously, BiondVax aimed to develop M-001, an influenza vaccine, but its Phase 3 trial did not achieve primary and secondary efficacy endpoints. The company is now pursuing other opportunities in infectious diseases.
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) has successfully closed its underwritten offering, selling 2,434,783 American Depositary Shares (ADS) at $4.95 each, raising approximately $12.1 million. A 30-day option for underwriters to purchase an additional 15% could increase total proceeds to about $13.8 million. The company plans to use the funds for general corporate purposes, including R&D and potential acquisitions. This follows the completion of a Phase 3 clinical trial for its influenza vaccine candidate M-001, which did not meet efficacy endpoints.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced a public offering of 2,434,783 American Depositary Shares (ADSs) priced at $4.95 each, aiming for gross proceeds of approximately $12.1 million. The offering will close around February 2, 2021, pending customary conditions. Proceeds will support general corporate purposes, including R&D and potential business acquisitions. Additionally, underwriters have a 30-day option to purchase 15% more ADSs for overallotments, potentially raising total gross proceeds to $13.8 million.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced plans for an underwritten public offering of its American Depositary Shares (ADSs) on January 28, 2021. The company may grant the underwriter a 30-day option to purchase an additional 15% of the ADSs to cover over-allotments. Proceeds from the offering will be used for general corporate purposes, including research and development and potential acquisitions. The offering is subject to market conditions, and no assurance is given on completion. The ADSs are offered under an effective registration statement with the SEC.
BiondVax Pharmaceuticals (BVXV) reported a significant turnaround in its third quarter 2020 financial results, achieving total operating income of NIS 55.6 million (approx. $16.1 million), compared to an operating loss of NIS 19.0 million in Q3 2019.
Net profit reached NIS 55.3 million (approx. $16.1 million), reversing a loss of NIS 19.4 million from the previous year. However, the company faces challenges as its Phase 3 clinical trial for M-001 failed, leading management to predict no future revenues from this product and decreased potential royalty payments.
BiondVax Pharmaceuticals (Nasdaq: BVXV) announced the appointment of Amir Reichman as CEO, effective March 2, 2021. Reichman, currently at GSK, will transition with founder Ron Babecoff, who will become a Senior Advisor. The change aims to leverage Reichman’s expertise to expand BiondVax’s pipeline in infectious diseases. Notably, the company is still recovering from the disappointing Phase 3 trial results of its flu vaccine candidate, M-001, which did not meet efficacy endpoints. BiondVax seeks to innovate and enhance its product offerings in the biopharmaceutical sector.
FAQ
What is the market cap of BiondVax Pharmaceuticals Ltd. (bvxv)?
What does BiondVax Pharmaceuticals Ltd. do?
What are NanoAbs?
What recent achievements has BiondVax made?
Who is Liat Halpert?
What services does Scinai Bioservices offer?
When are human clinical trials for the psoriasis NanoAb expected?
What are the potential applications of BiondVax's NanoAbs?
How is BiondVax planning to expand its CDMO business?
What regulatory approvals does BiondVax need?
Where can I find more information about BiondVax Pharmaceuticals Ltd.?
